ibrutinib,zilovertamab
abbvie,janssen
['leukemia', 'lymphoma', 'cll', 'mantle,(-dismantle)', ' ibru']
ziolvertamab and ibrutinib combination therapy demonstrated an overall response rate of 89.3% and 91.2% in patients with mantle cell lymphoma and chronic lymphocytic leukemia, respectively. #cll #ash22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.